Jones S E, Mennel R G, Brooks B, Westrick M A, Allison M A, Paulson R S, Tilmann K, Rea B
Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX.
J Clin Oncol. 1991 Oct;9(10):1736-9. doi: 10.1200/JCO.1991.9.10.1736.
A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen. Fifty-three patients who received 313 courses of therapy were assessable for response and toxicity. Median age was 48 years (range, 33 to 80 years), and the patients had received an average of 1.5 chemotherapy regimens before this study. Of 53 assessable patients, 24 (45%, or 42% of all entered patients) experienced partial responses (PRs) with a median duration of 6 months (range, 2 to 13 months). Nine (69%) of 13 assessable patients without prior doxorubicin treatment responded, compared with 15 (38%) of 40 with prior doxorubicin (P less than .05). Toxicity was generally mild with dose reductions necessitated more often by mucositis and/or diarrhea than by myelosuppression. One patient with prior high-dose doxorubicin treatment developed congestive heart failure. The combination of mitoxantrone, leucovorin, and infusional 5-FU is an active and well-tolerated regimen for metastatic breast cancer and deserves further evaluation in patients without prior doxorubicin therapy.
对57例既往接受过治疗的转移性乳腺癌患者给予米托蒽醌、亚叶酸钙（甲酰四氢叶酸）和氟尿嘧啶持续静脉滴注（5-FU）的新联合方案，以评估该方案的缓解率、缓解持续时间和毒性。接受313个疗程治疗的53例患者可评估缓解情况和毒性。中位年龄为48岁（范围33至80岁），这些患者在本研究之前平均接受过1.5种化疗方案。在53例可评估患者中，24例（45%，占所有入组患者的42%）出现部分缓解（PR），中位缓解持续时间为6个月（范围2至13个月）。13例既往未接受过阿霉素治疗的可评估患者中有9例（69%）缓解，而40例既往接受过阿霉素治疗的患者中有15例（38%）缓解（P<0.05）。毒性一般较轻，因粘膜炎和/或腹泻需要更频繁地降低剂量，而非骨髓抑制。1例既往接受过高剂量阿霉素治疗的患者发生充血性心力衰竭。米托蒽醌、亚叶酸钙和氟尿嘧啶持续静脉滴注联合方案对转移性乳腺癌是一种有效的且耐受性良好的方案，值得在既往未接受过阿霉素治疗的患者中进一步评估。
